BACKGROUND: In rats, prepulse inhibition (PPI) of acoustic startle is disrupted by systemic administration of dopaminergic agonists, such as the dopamine D3 receptor (D3R)-preferential agonist pramipexole (PPX). PPX has D3R-active (S) and -inactive (R) stereoisomers. Here, we tested the neuroanatomical and stereochemical selectivity of PPX effects on PPI. METHODS: (S)-PRA or (R)-PRA (0, 0.47, 1.42, 4.73 μmol/kg) was injected sc 15 min prior to PPI testing in adult male Sprague Dawley rats. In separate rats, (S)-PPX (0, 3, 10 μg/0.5μl/side, ic) was infused into the nucleus accumbens (NAc), caudodorsal striatum (CS), or olfactory tubercle/Islands of Calleja (ICj) 15 min prior to PPI testing. D3R expression in these brain regions was assessed using quantitative rt-PCR. The PPI-disruptive effects of systemic (S)-PPX were also tested after pretreatment with the D3R-selective antagonist, U99194 (10mg/kg). RESULTS: Systemic administration of PPX stereoisomers demonstrated a dose-dependent effect of (S)-PPX on PPI, while (R)-PPX had no effect on PPI. PPX decreased PPI when infused into the NAc and ICj, but not the CS. Quantitative rt-PCR revealed D3R expression in ICj>NAc>CS. The PPI-disruptive effects of PPX were prevented by U99194. CONCLUSION: The PPI-reducing effects of PPX are stereospecific for the D3R-active (S)-isomer, neuroanatomically preferential for the D3R-rich ventral vs. D3R poor caudodorsal striatum, and prevented by pharmacologic D3R blockade. These findings are consistent with the conclusion that PPX disrupts PPI via stimulation of mesolimbic D3Rs.
BACKGROUND: In rats, prepulse inhibition (PPI) of acoustic startle is disrupted by systemic administration of dopaminergic agonists, such as the dopamine D3 receptor (D3R)-preferential agonist pramipexole (PPX). PPX has D3R-active (S) and -inactive (R) stereoisomers. Here, we tested the neuroanatomical and stereochemical selectivity of PPX effects on PPI. METHODS: (S)-PRA or (R)-PRA (0, 0.47, 1.42, 4.73 μmol/kg) was injected sc 15 min prior to PPI testing in adult male Sprague Dawley rats. In separate rats, (S)-PPX (0, 3, 10 μg/0.5μl/side, ic) was infused into the nucleus accumbens (NAc), caudodorsal striatum (CS), or olfactory tubercle/Islands of Calleja (ICj) 15 min prior to PPI testing. D3R expression in these brain regions was assessed using quantitative rt-PCR. The PPI-disruptive effects of systemic (S)-PPX were also tested after pretreatment with the D3R-selective antagonist, U99194 (10mg/kg). RESULTS: Systemic administration of PPX stereoisomers demonstrated a dose-dependent effect of (S)-PPX on PPI, while (R)-PPX had no effect on PPI. PPX decreased PPI when infused into the NAc and ICj, but not the CS. Quantitative rt-PCR revealed D3R expression in ICj>NAc>CS. The PPI-disruptive effects of PPX were prevented by U99194. CONCLUSION: The PPI-reducing effects of PPX are stereospecific for the D3R-active (S)-isomer, neuroanatomically preferential for the D3R-rich ventral vs. D3R poor caudodorsal striatum, and prevented by pharmacologic D3R blockade. These findings are consistent with the conclusion that PPX disrupts PPI via stimulation of mesolimbic D3Rs.
Authors: Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods Journal: J Pharmacol Exp Ther Date: 2005-04-15 Impact factor: 4.030
Authors: Mei Gu; M M Iravani; M Irvani; J Mark Cooper; Diane King; Peter Jenner; Anthony H V Schapira Journal: J Neurochem Date: 2004-12 Impact factor: 5.372
Authors: P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross Journal: CNS Neurol Disord Drug Targets Date: 2006-02 Impact factor: 4.388
Authors: Neal R Swerdlow; Jody M Shoemaker; Michele J Bongiovanni; Alaina C Neary; Laura S Tochen; Richard L Saint Marie Journal: Pharmacol Biochem Behav Date: 2007-04-03 Impact factor: 3.533
Authors: V Audinot; A Newman-Tancredi; A Gobert; J M Rivet; M Brocco; F Lejeune; L Gluck; I Desposte; K Bervoets; A Dekeyne; M J Millan Journal: J Pharmacol Exp Ther Date: 1998-10 Impact factor: 4.030
Authors: Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu Journal: Ageing Res Rev Date: 2019-11-22 Impact factor: 10.895
Authors: Bernardo Stutz; Michael J Waterson; Matija Šestan-Peša; Marcelo O Dietrich; Mario Škarica; Nenad Sestan; Bence Racz; Aletta Magyar; Peter Sotonyi; Zhong-Wu Liu; Xiao-Bing Gao; Ferenc Matyas; Milan Stoiljkovic; Tamas L Horvath Journal: Mol Psychiatry Date: 2022-07-29 Impact factor: 13.437
Authors: Jodi E Gresack; Patricia A Seymour; Christopher J Schmidt; Victoria B Risbrough Journal: Psychopharmacology (Berl) Date: 2013-12-21 Impact factor: 4.530
Authors: Fernando G Vieira; Eva LaDow; Andy Moreno; Joshua D Kidd; Beth Levine; Kenneth Thompson; Alan Gill; Steven Finkbeiner; Steven Perrin Journal: PLoS One Date: 2014-12-19 Impact factor: 3.240